250 related articles for article (PubMed ID: 24598006)
21. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
22. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
23. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
24. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
25. 3D QSAR studies of 1,3,4-benzotriazepine derivatives as CCK2 receptor antagonists.
Kaur K; Talele TT
J Mol Graph Model; 2008 Nov; 27(4):409-20. PubMed ID: 18774323
[TBL] [Abstract][Full Text] [Related]
26. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
27. 3D QSAR studies on antimalarial alkoxylated and hydroxylated chalcones by CoMFA and CoMSIA.
Xue CX; Cui SY; Liu MC; Hu ZD; Fan BT
Eur J Med Chem; 2004 Sep; 39(9):745-53. PubMed ID: 15337287
[TBL] [Abstract][Full Text] [Related]
28. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
29. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
30. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
Zhang J; Wang JL; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Bioorg Med Chem; 2012 Jul; 20(14):4208-16. PubMed ID: 22727371
[TBL] [Abstract][Full Text] [Related]
32. 3D-QSAR studies of substituted 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists.
Aher YD; Agrawal A; Bharatam PV; Garg P
J Mol Model; 2007 Apr; 13(4):519-29. PubMed ID: 17345108
[TBL] [Abstract][Full Text] [Related]
33. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
34. Development of CoMFA models of affinity and selectivity to angiotensin II type-1 and type-2 receptors.
Sköld C; Karlén A
J Mol Graph Model; 2007 Jul; 26(1):145-53. PubMed ID: 17161636
[TBL] [Abstract][Full Text] [Related]
35. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
36. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
37. Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists.
Sindhu T; Srinivasan P
J Recept Signal Transduct Res; 2014 Aug; 34(4):241-53. PubMed ID: 25072161
[TBL] [Abstract][Full Text] [Related]
38. Receptor-based QSAR study for a series of 3,3-disubstituted-5-aryl oxindoles and 6-aryl benzimidazol-2-ones derivatives as progesterone receptor inhibitors.
Wang JH; Hou QQ; Tang K; Cheng XL; Dong LH; Liu YJ; Liu CB
SAR QSAR Environ Res; 2011 Oct; 22(7-8):775-99. PubMed ID: 22004567
[TBL] [Abstract][Full Text] [Related]
39. 3D-QSAR study of 8-azabicyclo[3.2.1] octane analogs antagonists of cholinergic receptor.
Verma SM; Razdan BK; Sasmal D
Bioorg Med Chem Lett; 2009 Jun; 19(11):3108-12. PubMed ID: 19419864
[TBL] [Abstract][Full Text] [Related]
40. Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase.
Wang Z; Chen Z; Li J; Huang J; Zheng C; Liu JP
J Biomol Struct Dyn; 2020 Mar; 38(4):1071-1082. PubMed ID: 30915896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
